Work

Daratumumab – breakthrough drug in multiple myeloma therapy

Year: 2014

Type: article

Abstract: Multiple myeloma (MM) remains incurable despite important recent advances in treatment. Over the last 2 years, an anti-CD38 monoclonal antibody daratumumab (DARA) has emerged as a breakthrough targeted therapy for patients with MM. Early-stage clinical trials have found DARA to be safe and to have encouraging clinical activity as a single agent and in combination with lenalidomide in heavily pretreated, relapsed patients in whom other novel agents (such as bortezomib, thalidomide and lenalidomide) as well as stem cell transplant has already failed. This review discusses the preclinical and clinical development of DARA, its pathophysiological basis, and its prospects for future use in MM.

Source: Postępy Higieny i Medycyny Doświadczalnej

DOI: 10.5604/17322693.1129819

Authors: Artur Jurczyszyn, Agata Kosmaczewska, Aleksander B. Skotnicki

Institutions: Szpital Uniwersytecki w Krakowie, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences

Language: Polish

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W2313597551

FWCI: 0.647

Cites: 65

Cited by: 3

Related to: 10